Table 6. Response rates according to treatment arm.
|
ECF
|
EOF
|
ECX
|
EOX
|
|||||
|---|---|---|---|---|---|---|---|---|
| No. of pts | % | No. of pts | % | No. of pts | % | No. of pts | % | |
| CR | 1 | 2 | 3 | 6 | 4 | 9 | 1 | 2 |
| PR | 14 | 29 | 18 | 33 | 12 | 26 | 22 | 46 |
| Overall (CR+PR) | 15 | 31 | 21 | 39 | 16 | 35 | 23 | 48 |
| 95% CI | (18.7–46.3) | (25.9–53.1) | (21.4–50.3) | (33.3–62.8) | ||||
| Stable disease | 17 | 36 | 16 | 30 | 14 | 30 | 15 | 31 |
| PD | 13 | 27 | 11 | 20 | 11 | 24 | 7 | 15 |
| No assessment available | 3 | 6 | 6 | 11 | 5 | 11 | 3 | 6 |
Pts=patients; ECF=epirubicin, cisplatin, 5-fluorouracil; ECX=epirubicin, cisplatin, capecitabine; EOF=epirubicin, oxaliplatin, 5-fluorouracil; EOX=epirubicin, oxaliplatin, capecitabine; CR=complete response; PR=partial response; PD=progressive disease; 95% CI=95% confidence interval.